Nephrotoxicity of rapamycin: an emerging problem in clinical medicine.

Suppr

超能文献

作者信息

Marti Hans-Peter, Frey Felix J

出版信息

Nephrol Dial Transplant. 2005 Jan;20(1):13-5. doi: 10.1093/ndt/gfh639.

DOI:10.1093/ndt/gfh639

PMID:15632347

Abstract

摘要

相似文献

Nephrotoxicity of rapamycin: an emerging problem in clinical medicine.

Nephrol Dial Transplant. 2005 Jan;20(1):13-5. doi: 10.1093/ndt/gfh639.

Kidney transplant recipients and the incidence of adverse reactions to cyclosporin.

Saudi Med J. 2004 Oct;25(10):1499-500.

De novo immunosuppression with mammalian target of rapamycin inhibitors and posttransplantation malignancy in focus.

Transplant Proc. 2009 Jul-Aug;41(6 Suppl):S42-4. doi: 10.1016/j.transproceed.2009.06.158. Epub 2009 Jul 9.

Rapamycin for treatment of chronic allograft nephropathy in renal transplant patients.

J Am Soc Nephrol. 2005 Dec;16(12):3755-62. doi: 10.1681/ASN.2005060635. Epub 2005 Oct 19.

No robust conclusions to be drawn from clinical trials in the absence of an adequate control group.

Transpl Int. 2007 Jan;20(1):25-6. doi: 10.1111/j.1432-2277.2006.00428.x.

Multidisciplinary insights on clinical guidance for the use of proliferation signal inhibitors in heart transplantation.

J Heart Lung Transplant. 2008 Feb;27(2):141-9. doi: 10.1016/j.healun.2007.08.014.

Sirolimus in renal transplantation.

Nephrol Dial Transplant. 2007 Sep;22 Suppl 8:viii61-viii65. doi: 10.1093/ndt/gfm652.

Sirolimus-based therapy for kidney transplantation from expanded criteria donors.

Transplantation. 2009 Apr 27;87(8 Suppl):S11-3. doi: 10.1097/TP.0b013e3181a058a1.

Concentration control: a key to phase I development of immunosuppressive agents.

Transplant Proc. 1994 Dec;26(6):3203-4.

Colonic perforation associated with leukocytoclastic vasculitis caused by Sirolimus toxicity following renal transplantation.

Transpl Int. 2006 May;19(5):430-1. doi: 10.1111/j.1432-2277.2006.00276.x.

引用本文的文献

Targeting mitochondrial dysfunction: an innovative strategy for treating renal fibrosis.

Mol Cell Biochem. 2025 Apr 29. doi: 10.1007/s11010-025-05297-w.

Toxicology of pharmaceutical and nutritional longevity compounds.

Expert Rev Mol Med. 2023 Jun 22;25:e28. doi: 10.1017/erm.2023.18.

Mitochondrial quality control in kidney injury and repair.

Nat Rev Nephrol. 2021 May;17(5):299-318. doi: 10.1038/s41581-020-00369-0. Epub 2020 Nov 24.

Nanotoxicology of an Elastin-like Polypeptide Rapamycin Formulation for Breast Cancer.

Biomacromolecules. 2020 Mar 9;21(3):1091-1102. doi: 10.1021/acs.biomac.9b01431. Epub 2020 Feb 6.

Berunda Polypeptides: Biheaded Rapamycin Carriers for Subcutaneous Treatment of Autoimmune Dry Eye Disease.

Mol Pharm. 2019 Jul 1;16(7):3024-3039. doi: 10.1021/acs.molpharmaceut.9b00263. Epub 2019 May 30.

Clinical Experience of Sirolimus Regarding Efficacy and Safety in Systemic Lupus Erythematosus.

Front Pharmacol. 2019 Feb 6;10:82. doi: 10.3389/fphar.2019.00082. eCollection 2019.

Efficacy and safety of low-dose Sirolimus in Lymphangioleiomyomatosis.

Orphanet J Rare Dis. 2018 Nov 14;13(1):204. doi: 10.1186/s13023-018-0946-8.

Intracellular Delivery of Rapamycin From FKBP Elastin-Like Polypeptides Is Consistent With Macropinocytosis.

Front Pharmacol. 2018 Oct 17;9:1184. doi: 10.3389/fphar.2018.01184. eCollection 2018.

The Human FSGS-Causing R431C Mutation Induces Dysregulated PI3K/AKT/mTOR/Rac1 Signaling in Podocytes.

J Am Soc Nephrol. 2018 Aug;29(8):2110-2122. doi: 10.1681/ASN.2017121338. Epub 2018 Jul 12.

Berunda Polypeptides: Multi-Headed Fusion Proteins Promote Subcutaneous Administration of Rapamycin to Breast Cancer .

Theranostics. 2017 Aug 29;7(16):3856-3872. doi: 10.7150/thno.19981. eCollection 2017.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验